Alkali Therapy for Kidney Complication
What You Need to Know Before You Apply
What is the purpose of this trial?
Lower serum bicarbonate levels, even within the normal laboratory range, in kidney transplant recipients (KTRs) are associated with an increased risk of graft loss, cardiovascular events and mortality. Because acid retention is common in KTRs, it is plausible that alkali therapy in KTRs may also result in improved vascular and graft function. The investigators will perform a randomized, double-blinded, placebo-controlled, 12 month study in 120 KTRs to examine the effect of sodium bicarbonate therapy on surrogate markers of CVD and graft function. The overall hypothesis is that treatment with bicarbonate will improve indicators of vascular and graft function in KTRs by decreasing complement activation.
Do I need to stop my current medications for the trial?
The trial does not specify if you need to stop your current medications, but you must have a stable immunosuppression and anti-hypertensive regimen before joining. You cannot take medications that interact with the trial's agents, like sildenafil with nitroglycerin.
Is alkali therapy, like sodium bicarbonate, safe for humans?
How is the drug sodium bicarbonate unique in treating kidney complications?
Sodium bicarbonate is unique because it helps correct acid levels in the body, which can preserve kidney function in chronic kidney disease (CKD) patients. Unlike other treatments, it specifically targets metabolic acidosis (a condition where the body produces too much acid or the kidneys cannot remove enough acid) and may reduce harmful substances like angiotensin II that can damage the kidneys.15678
Who Is on the Research Team?
Jessica Kendrick, MD MPH
Principal Investigator
University of Colorado Denver | Anschutz
Are You a Good Fit for This Trial?
This trial is for kidney transplant recipients aged 18-80 with stable health, not on conflicting meds or treatments, and a BMI under 40. They should have had their transplant at least a year ago, be on specific immunosuppressants, and have certain levels of serum bicarbonate and eGFR—a measure of kidney function.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive sodium bicarbonate or placebo for 12 months to assess effects on vascular and graft function
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- Sodium bicarbonate
Sodium bicarbonate is already approved in United States, European Union, Canada for the following indications:
- Metabolic acidosis
- Antacid
- Heartburn relief
- Metabolic acidosis
- Antacid
- Metabolic acidosis
- Antacid
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Colorado, Denver
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator